Differential Impact of TKI Therapy on the Natural Course of CML Determines Risk Stratification of Additional Cytogenetic Abnormalities

被引：0
|
作者：
Gong, Zimu [1 ]
Bai, Shi [1 ]
Chen, Zi [1 ]
Wang, Wei [1 ]
Miranda, Roberto N. [1 ]
Medeiros, L. Jeffrey [1 ]
Hu, Shimin [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
MODERN PATHOLOGY | 2017年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
1408
引用
收藏
页码：351A / 351A
页数：1
相关论文
共 7 条
  • [1] Differential Impact of TKI Therapy on the Natural Course of CML Determines Risk Stratification of Additional Cytogenetic Abnormalities
    Gong, Zimu
    Bai, Shi
    Chen, Zi
    Wang, Wei
    Miranda, Roberto N.
    Medeiros, L. Jeffrey
    Hu, Shimin
    LABORATORY INVESTIGATION, 2017, 97 : 351A - 351A
  • [2] The Impact of Additional Chromosome Abnormalities and Variant Translocations at Diagnosis of CML in the TKI era: A Single Institution Experience
    D'Achille, Pina
    Wall, Meaghan
    Campbell, Lynda
    CHROMOSOME RESEARCH, 2013, 21 : S83 - S83
  • [3] Impact of Additional Cytogenetic Abnormalities and Variant t(9;22) at Diagnosis on Prognosis of Childhood Chronic Myelogenous Leukemia : The Experience of the International Registry for CML in Children and Adolescents (I-CML-Ped Study)
    Millot, Frederic
    Guilhot, Joelle
    Suttorp, Meinolf
    Sedlacek, Pietr
    de Bont, Eveline S. J. M.
    Li, Chi Kong
    Kalwak, Krzysztof
    Lausen, Birgitte
    Srdjana, Culic
    Dresse, Marie-Francoise
    Biondi, Andrea
    Baruchel, Andre
    Brizard, Francoise
    BLOOD, 2014, 124 (21)
  • [4] Natural Course of the American Thyroid Association Response to Therapy Statuses (Dynamic Risk Stratification) in Differentiated Thyroid Cancer
    Mukhtar, Noha
    Aljamei, Hadeel
    Aljomaiah, Abeer
    Moria, Yosra
    Alzahrani, Ali S.
    EUROPEAN THYROID JOURNAL, 2021, 10 (03) : 198 - 207
  • [5] Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy
    Chen, Z.
    Cortes, J. E.
    Jorgensen, J. L.
    Wang, W.
    Yin, C. C.
    You, M. J.
    Jabbour, E.
    Kantarjian, H. M.
    Medeiros, L. J.
    Hu, S.
    LEUKEMIA, 2016, 30 (07) : 1606 - 1609
  • [6] Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy
    Z Chen
    J E Cortes
    J L Jorgensen
    W Wang
    C C Yin
    M J You
    E Jabbour
    H M Kantarjian
    L J Medeiros
    S Hu
    Leukemia, 2016, 30 : 1606 - 1609
  • [7] Prospective Assessment of Co-Morbidities and Framingham Risk Score in Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients and Its Impact on Clinical Outcomes Following Frontline TKI Therapy: Toronto CML Genomic Alliance in Greater Toronto Area & Ontario (TCGA-GTA)
    Chiu, May
    Gupta, Gopila
    Perusini, Maria Agustina
    Al-Shaibani, Eshrak
    Ho, Jenny
    Kim, Dennis Dong Hwan
    BLOOD, 2023, 142
1